Premium
INHIBITION OF PROSTAGLANDIN‐INDUCED UTERINE ACTIVITY BY NIFEDIPINE
Author(s) -
Anderson K.E.,
Ingemarsson I.,
Ulmsten U.,
Wingerup L.
Publication year - 1979
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1979.tb10590.x
Subject(s) - nifedipine , medicine , uterine contraction , prostaglandin , abortion , pregnancy , alpha (finance) , oxytocin , uterus , endocrinology , calcium , biology , surgery , construct validity , patient satisfaction , genetics
Summary The effects of the calcium antagonist, nifedipine, on uterine activity induced by prostaglandins F 2α (PGFZ 2α ) and E 2 (PGE 2 ) were studied in women undergoingtherapeutic midtrimester abortion, and in patients with a missed abortion in the 16th to 27th week of pregnancy. In the five subjects receiving intra‐amniotic PGF 2α (25 to 40 mg) for midtrimester abortion, nifedipine (30 mg orally) decreased uterine activity from a mean of 372 to 203 Montevideo Units. The effect on the intensity of the contractions was pronounced; frequency and basal tone were little affected. In patients with missed abortion, uterine contractions were induced by extra‐amniotic application of PGE 2 (0.5 to 1.5 mg) in a viscous gel. The activity was often more irregular than that in the women receiving intra‐amniotic PGF 2α . However, nifedipine (30 mg orally) had a marked inhibitory effect on the uterine contractions. It is concluded that nifedipine can be used for treatment of uterine hyperactivity induced by prostaglandins. Combined treatment with β 2 ‐adrenoceptor stimulants might be considered.